Increase of Plasma TGF-beta1 Level in Colorectal Cancer Patients.
- Author:
Chang Ki LIM
1
;
In Young CHOI
;
Hoon SHIN
;
Min Hee RYU
;
Seung Kook SOHN
;
Seung Won JIN
Author Information
1. Central Research Institute, Hanmi Pharmaceutical Co., Ltd., Korea. swjin@hanmi.co.kr
- Publication Type:Original Article
- Keywords:
CEA;
Colorectal cancer;
ELISA;
TGF-beta1;
Tumor marker
- MeSH:
Carcinoembryonic Antigen;
Colorectal Neoplasms*;
Enzyme-Linked Immunosorbent Assay;
Humans;
Plasma*;
Sensitivity and Specificity;
Transforming Growth Factor beta1*
- From:Journal of the Korean Society of Coloproctology
2001;17(3):135-140
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Many kinds of malignant tissues, including colorectal cancer were reported to overexpress transforming growth factor-beta1 (TGF-beta1) gene. However, little work has been done on the circulating TGF-beta1 and the association of TGF-beta1 with progression in patients with malignant tumors. In this study, we measured the plasma level of TGF-beta1 in colorectal cancer patients. METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma TGF-beta1 level in 52 colorectal cancer patients and 290 normal controls. And carcinoembryonic antigen (CEA) as a tumor marker was compared with TGF-beta1 in the aspects of sensitivity and specificity. RESULTS: The mean plasma TGF-beta1 levels were 1.219 +/- 0.834 (0.272~5.772) ng/mL in normal control and 8.207 +/- 2.428 (1.392~39.241) ng/mL in colorectal cancer. In comparison with CEA, TGF-beta1 is more potent in cancer diagnostic sensitivity. CONCLUSIONS: The results of this study suggest that the plasma TGF-beta1 level can be a useful tumor marker in colorectal cancer patients.
